You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePramipexole
Accession NumberDB00413  (APRD00156)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Pramipexole is a medication indicated for treating Parkinson’s disease and restless legs syndrome (RLS). It is also sometimes used off-label as a treatment for cluster headache or to counteract the problems with low libido experienced by some users of SSRI antidepressant drugs. Pramipexole has shown robust effects on pilot studies in bipolar disorder. Pramipexole is classified as a non-ergoline dopamine agonist.

Structure
Thumb
Synonyms
(-)-Pramipexole
(S)-N  6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N(sup 6)-propyl-, (S)-
Pramipexol
Pramipexole
Pramipexolum
External Identifiers
  • PNU 98528
  • SND 919 Cl 2Y
  • SUD 919 CL 24
  • U 98528 E
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Pramipexoletablet1.5 mgoralActavis Pharma Company2009-04-15Not applicableCanada
Act Pramipexoletablet1.0 mgoralActavis Pharma Company2009-04-15Not applicableCanada
Act Pramipexoletablet0.5 mgoralActavis Pharma Company2009-04-15Not applicableCanada
Act Pramipexoletablet0.25 mgoralActavis Pharma Company2009-04-15Not applicableCanada
Auro-pramipexoletablet0.125 mgoralAuro Pharma Inc2014-04-29Not applicableCanada
Auro-pramipexoletablet1 mgoralAuro Pharma Inc2014-04-29Not applicableCanada
Auro-pramipexoletablet0.5 mgoralAuro Pharma Inc2014-04-29Not applicableCanada
Auro-pramipexoletablet1.5 mgoralAuro Pharma IncNot applicableNot applicableCanada
Auro-pramipexoletablet0.25 mgoralAuro Pharma Inc2014-04-29Not applicableCanada
Ava-pramipexoletablet0.25 mgoralAvanstra Inc2011-09-192014-08-21Canada
Ava-pramipexoletablet1.0 mgoralAvanstra Inc2011-09-192014-08-21Canada
Ava-pramipexoletablet0.5 mgoralAvanstra Inc2011-09-192014-08-21Canada
Ava-pramipexoletablet1.5 mgoralAvanstra Inc2011-09-192014-08-21Canada
Dom-pramipexoletablet1.5 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-pramipexoletablet1.0 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-pramipexoletablet0.5 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-pramipexoletablet0.25 mgoralDominion Pharmacal2012-09-26Not applicableCanada
Mirapextablet.5 mg/1oralRebel Distributors Corp2004-01-01Not applicableUs
Mirapextablet.75 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2007-10-01Not applicableUs
Mirapextablet.25 mg/1oralPhysicians Total Care, Inc.2007-03-23Not applicableUs
Mirapextablet.25 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2004-01-01Not applicableUs
Mirapextablet1.0 mgoralBoehringer Ingelheim (Canada) Ltd Ltee1998-02-26Not applicableCanada
Mirapextablet.125 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2004-01-01Not applicableUs
Mirapextablet0.25 mgoralBoehringer Ingelheim (Canada) Ltd Ltee1998-02-26Not applicableCanada
Mirapextablet.25 mg/1oralCardinal Health2004-01-01Not applicableUs
Mirapextablet1 mg/1oralPhysicians Total Care, Inc.2007-01-09Not applicableUs
Mirapextablet1.5 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2004-01-01Not applicableUs
Mirapextablet0.125 mgoralBoehringer Ingelheim (Canada) Ltd Ltee2008-07-09Not applicableCanada
Mirapextablet.5 mg/1oralPhysicians Total Care, Inc.2005-09-12Not applicableUs
Mirapextablet1 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2004-01-01Not applicableUs
Mirapextablet0.5 mgoralBoehringer Ingelheim (Canada) Ltd Ltee2000-03-17Not applicableCanada
Mirapextablet.125 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-10-05Not applicableUs
Mirapextablet.125 mg/1oralPhysicians Total Care, Inc.2003-09-04Not applicableUs
Mirapextablet.5 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2004-01-01Not applicableUs
Mirapextablet1.5 mgoralBoehringer Ingelheim (Canada) Ltd Ltee1998-02-26Not applicableCanada
Mirapex ERtablet, extended release3.75 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2011-06-18Not applicableUs
Mirapex ERtablet, extended release2.25 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2011-06-18Not applicableUs
Mirapex ERtablet, extended release4.5 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2010-02-22Not applicableUs
Mirapex ERtablet, extended release.75 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2010-02-22Not applicableUs
Mirapex ERtablet, extended release3 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2010-02-22Not applicableUs
Mirapex ERtablet, extended release1.5 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2010-02-22Not applicableUs
Mirapex ERtablet, extended release.375 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2010-02-22Not applicableUs
Mylan-pramipexoletablet1.5 mgoralMylan Pharmaceuticals Ulc2011-11-23Not applicableCanada
Mylan-pramipexoletablet1 mgoralMylan Pharmaceuticals Ulc2011-11-23Not applicableCanada
Mylan-pramipexoletablet0.5 mgoralMylan Pharmaceuticals Ulc2011-11-23Not applicableCanada
Mylan-pramipexoletablet0.25 mgoralMylan Pharmaceuticals Ulc2011-11-23Not applicableCanada
Ntp-pramipexoletablet1.5 mgoralNt Pharma Canada LtdNot applicableNot applicableCanada
Ntp-pramipexoletablet1.0 mgoralNt Pharma Canada LtdNot applicableNot applicableCanada
Ntp-pramipexoletablet0.5 mgoralNt Pharma Canada LtdNot applicableNot applicableCanada
Ntp-pramipexoletablet0.25 mgoralNt Pharma Canada LtdNot applicableNot applicableCanada
Nu-pramipexoletablet1.5 mgoralNu Pharm IncNot applicableNot applicableCanada
PMS-pramipexoletablet0.25 mgoralPharmascience Inc2006-12-29Not applicableCanada
PMS-pramipexoletablet1.0 mgoralPharmascience Inc2006-12-29Not applicableCanada
PMS-pramipexoletablet0.50 mgoralPharmascience Inc2006-12-29Not applicableCanada
PMS-pramipexoletablet1.5 mgoralPharmascience Inc2006-12-29Not applicableCanada
Pramipexoletablet0.5 mgoralSanis Health Inc2011-07-21Not applicableCanada
Pramipexoletablet0.25 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Pramipexoletablet0.25 mgoralSanis Health Inc2011-07-21Not applicableCanada
Pramipexoletablet1.5 mgoralSivem Pharmaceuticals Ulc2009-04-09Not applicableCanada
Pramipexoletablet1.5 mgoralPro Doc Limitee2009-06-15Not applicableCanada
Pramipexoletablet1 mgoralSivem Pharmaceuticals Ulc2009-04-09Not applicableCanada
Pramipexoletablet1.0 mgoralPro Doc Limitee2009-06-15Not applicableCanada
Pramipexoletablet0.5 mgoralSivem Pharmaceuticals Ulc2009-04-09Not applicableCanada
Pramipexoletablet1.5 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Pramipexoletablet0.50 mgoralPro Doc Limitee2009-06-15Not applicableCanada
Pramipexoletablet0.25 mgoralSivem Pharmaceuticals Ulc2009-04-09Not applicableCanada
Pramipexoletablet1.5 mgoralSanis Health Inc2011-07-21Not applicableCanada
Pramipexoletablet1.0 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Pramipexoletablet0.25 mgoralPro Doc Limitee2009-06-15Not applicableCanada
Pramipexoletablet1 mgoralSanis Health Inc2011-07-21Not applicableCanada
Pramipexoletablet0.5 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Sandoz Pramipexoletablet0.5 mgoralSandoz Canada Incorporated2008-08-14Not applicableCanada
Sandoz Pramipexoletablet1.5 mgoralSandoz Canada Incorporated2008-08-14Not applicableCanada
Sandoz Pramipexoletablet0.25 mgoralSandoz Canada Incorporated2008-08-14Not applicableCanada
Sandoz Pramipexoletablet1.0 mgoralSandoz Canada Incorporated2008-08-14Not applicableCanada
Teva-pramipexoletablet1.5 mgoralTeva Canada Limited2006-12-07Not applicableCanada
Teva-pramipexoletablet1.0 mgoralTeva Canada Limited2006-12-07Not applicableCanada
Teva-pramipexoletablet0.5 mgoralTeva Canada Limited2006-12-07Not applicableCanada
Teva-pramipexoletablet0.25 mgoralTeva Canada Limited2006-12-07Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-pramipexoletablet0.25 mgoralApotex Inc2007-02-26Not applicableCanada
Apo-pramipexoletablet0.75 mgoralApotex IncNot applicableNot applicableCanada
Apo-pramipexoletablet0.125 mgoralApotex IncNot applicableNot applicableCanada
Apo-pramipexoletablet1.5 mgoralApotex Inc2007-02-26Not applicableCanada
Apo-pramipexoletablet1.0 mgoralApotex Inc2007-02-26Not applicableCanada
Apo-pramipexoletablet0.5 mgoralApotex Inc2007-02-26Not applicableCanada
Pramipexoletablet.5 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2013-05-23Not applicableUs
Pramipexoletablet1.5 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2013-05-23Not applicableUs
Pramipexoletablet.25 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2013-05-23Not applicableUs
Pramipexoletablet1.5 mg/1oralCamber Pharmaceuticals, Inc.2015-08-01Not applicableUs
Pramipexoletablet.125 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2013-05-23Not applicableUs
Pramipexoletablet1 mg/1oralCamber Pharmaceuticals, Inc.2015-08-01Not applicableUs
Pramipexoletablet.75 mg/1oralCamber Pharmaceuticals, Inc.2015-08-01Not applicableUs
Pramipexoletablet.5 mg/1oralCamber Pharmaceuticals, Inc.2015-08-01Not applicableUs
Pramipexoletablet.25 mg/1oralCamber Pharmaceuticals, Inc.2015-08-01Not applicableUs
Pramipexoletablet1 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2013-05-23Not applicableUs
Pramipexoletablet.75 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2013-05-23Not applicableUs
Pramipexoletablet.125 mg/1oralCamber Pharmaceuticals, Inc.2015-08-01Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralSandoz Inc2010-07-06Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralVensun Pharmaceuticals, Inc.2014-10-29Not applicableUs
Pramipexole Dihydrochloridetablet1 mg/1oralBreckenridge Pharmaceutical, Inc.2010-10-09Not applicableUs
Pramipexole Dihydrochloridetablet.5 mg/1oralbryant ranch prepack2010-07-10Not applicableUs
Pramipexole Dihydrochloridetablet.5 mg/1oralAurobindo Pharma Limited2012-10-26Not applicableUs
Pramipexole Dihydrochloridetablet1.5 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-07-10Not applicableUs
Pramipexole Dihydrochloridetablet1 mg/1oralCitron Pharma LLC2012-10-26Not applicableUs
Pramipexole Dihydrochloridetablet1.5 mg/1oralTorrent Pharmaceuticals Limited2010-10-08Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralKAISER FOUNDATION HOSPITALS2011-02-15Not applicableUs
Pramipexole Dihydrochloridetablet.5 mg/1oralSTAT Rx USA LLC2010-01-01Not applicableUs
Pramipexole Dihydrochloridetablet.5 mg/1oralVensun Pharmaceuticals, Inc.2014-10-29Not applicableUs
Pramipexole Dihydrochloridetablet1 mg/1oralPhysicians Total Care, Inc.2010-04-20Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralStrides Arcolab Limited2014-06-17Not applicableUs
Pramipexole Dihydrochloridetablet1 mg/1oralAurobindo Pharma Limited2012-10-26Not applicableUs
Pramipexole Dihydrochloridetablet.25 mg/1oralGlenmark Pharmaceuticals Inc., Usa2010-10-08Not applicableUs
Pramipexole Dihydrochloridetablet.5 mg/1oralSandoz Inc2010-07-06Not applicableUs
Pramipexole Dihydrochloridetablet.75 mg/1oralMylan Pharmaceuticals Inc.2010-11-04Not applicableUs
Pramipexole Dihydrochloridetablet.25 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-07-06Not applicableUs
Pramipexole Dihydrochloridetablet.5 mg/1oralScie Gen Pharmaceuticals Inc2014-10-29Not applicableUs
Pramipexole Dihydrochloridetablet, extended release1.5 mg/1oralDr. Reddy's Laboratories Limited2015-08-14Not applicableUs
Pramipexole Dihydrochloridetablet1.5 mg/1oralGolden State Medical Supply, Inc2014-10-29Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralCadila Healthcare Limited2010-07-10Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralCarilion Materials Management2010-10-08Not applicableUs
Pramipexole Dihydrochloridetablet.5 mg/1oralQualitest Pharmaceuticals2013-07-152016-01-20Us
Pramipexole Dihydrochloridetablet.75 mg/1oralGlenmark Pharmaceuticals Inc., Usa2016-01-31Not applicableUs
Pramipexole Dihydrochloridetablet1 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-01Not applicableUs
Pramipexole Dihydrochloridetablet1.5 mg/1oralAv Kare, Inc.2013-09-05Not applicableUs
Pramipexole Dihydrochloridetablet.5 mg/1oralBreckenridge Pharmaceutical, Inc.2010-10-09Not applicableUs
Pramipexole Dihydrochloridetablet.25 mg/1oralbryant ranch prepack2010-10-08Not applicableUs
Pramipexole Dihydrochloridetablet.25 mg/1oralAurobindo Pharma Limited2012-10-26Not applicableUs
Pramipexole Dihydrochloridetablet1 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-07-10Not applicableUs
Pramipexole Dihydrochloridetablet.75 mg/1oralCitron Pharma LLC2012-10-26Not applicableUs
Pramipexole Dihydrochloridetablet1 mg/1oralTorrent Pharmaceuticals Limited2010-10-08Not applicableUs
Pramipexole Dihydrochloridetablet1.5 mg/1oralMylan Pharmaceuticals Inc.2010-11-04Not applicableUs
Pramipexole Dihydrochloridetablet1.5 mg/1oralMacleods Pharmaceuticals Limited2012-09-21Not applicableUs
Pramipexole Dihydrochloridetablet.25 mg/1oralScie Gen Pharmaceuticals Inc2014-10-29Not applicableUs
Pramipexole Dihydrochloridetablet, extended release.75 mg/1oralDr. Reddy's Laboratories Limited2015-08-14Not applicableUs
Pramipexole Dihydrochloridetablet1 mg/1oralGolden State Medical Supply, Inc2014-10-29Not applicableUs
Pramipexole Dihydrochloridetablet1.5 mg/1oralStrides Arcolab Limited2014-06-17Not applicableUs
Pramipexole Dihydrochloridetablet1 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Pramipexole Dihydrochloridetablet.25 mg/1oralQualitest Pharmaceuticals2013-07-152016-01-20Us
Pramipexole Dihydrochloridetablet1.5 mg/1oralWatson Pharma, Inc.2010-10-08Not applicableUs
Pramipexole Dihydrochloridetablet1 mg/1oralAv Kare, Inc.2013-09-05Not applicableUs
Pramipexole Dihydrochloridetablet.25 mg/1oralBreckenridge Pharmaceutical, Inc.2010-10-09Not applicableUs
Pramipexole Dihydrochloridetablet1.5 mg/1oralEndo Pharmaceuticals Inc. DBA Endo Generic Products2010-10-09Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralAurobindo Pharma Limited2012-10-26Not applicableUs
Pramipexole Dihydrochloridetablet.5 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-07-10Not applicableUs
Pramipexole Dihydrochloridetablet.5 mg/1oralCitron Pharma LLC2012-10-26Not applicableUs
Pramipexole Dihydrochloridetablet.5 mg/1oralTorrent Pharmaceuticals Limited2010-10-08Not applicableUs
Pramipexole Dihydrochloridetablet1 mg/1oralMylan Pharmaceuticals Inc.2010-11-04Not applicableUs
Pramipexole Dihydrochloridetablet1 mg/1oralMacleods Pharmaceuticals Limited2012-09-21Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralScie Gen Pharmaceuticals Inc2014-10-29Not applicableUs
Pramipexole Dihydrochloridetablet, extended release.375 mg/1oralDr. Reddy's Laboratories Limited2015-08-14Not applicableUs
Pramipexole Dihydrochloridetablet.5 mg/1oralGolden State Medical Supply, Inc2014-10-29Not applicableUs
Pramipexole Dihydrochloridetablet1 mg/1oralStrides Arcolab Limited2014-06-17Not applicableUs
Pramipexole Dihydrochloridetablet.5 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralQualitest Pharmaceuticals2013-07-152016-01-20Us
Pramipexole Dihydrochloridetablet1 mg/1oralWatson Pharma, Inc.2010-10-08Not applicableUs
Pramipexole Dihydrochloridetablet.5 mg/1oralAv Kare, Inc.2013-09-05Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralBreckenridge Pharmaceutical, Inc.2010-10-09Not applicableUs
Pramipexole Dihydrochloridetablet.25 mg/1oralCardinal Health2010-11-17Not applicableUs
Pramipexole Dihydrochloridetablet1 mg/1oralEndo Pharmaceuticals Inc. DBA Endo Generic Products2010-10-09Not applicableUs
Pramipexole Dihydrochloridetablet1.5 mg/1oralCadila Healthcare Limited2010-07-10Not applicableUs
Pramipexole Dihydrochloridetablet.25 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-07-10Not applicableUs
Pramipexole Dihydrochloridetablet.25 mg/1oralCitron Pharma LLC2012-10-26Not applicableUs
Pramipexole Dihydrochloridetablet.25 mg/1oralTorrent Pharmaceuticals Limited2010-10-08Not applicableUs
Pramipexole Dihydrochloridetablet.5 mg/1oralMylan Pharmaceuticals Inc.2010-11-04Not applicableUs
Pramipexole Dihydrochloridetablet.5 mg/1oralMacleods Pharmaceuticals Limited2012-09-21Not applicableUs
Pramipexole Dihydrochloridetablet1.5 mg/1oralVensun Pharmaceuticals, Inc.2014-10-29Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralPhysicians Total Care, Inc.2011-04-08Not applicableUs
Pramipexole Dihydrochloridetablet.25 mg/1oralGolden State Medical Supply, Inc2014-10-29Not applicableUs
Pramipexole Dihydrochloridetablet.75 mg/1oralStrides Arcolab Limited2014-06-17Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralAmerican Health Packaging2014-07-31Not applicableUs
Pramipexole Dihydrochloridetablet1.5 mg/1oralGlenmark Pharmaceuticals Inc., Usa2010-10-08Not applicableUs
Pramipexole Dihydrochloridetablet.75 mg/1oralSandoz Inc2010-10-08Not applicableUs
Pramipexole Dihydrochloridetablet.5 mg/1oralWatson Pharma, Inc.2010-10-08Not applicableUs
Pramipexole Dihydrochloridetablet.25 mg/1oralAv Kare, Inc.2013-09-05Not applicableUs
Pramipexole Dihydrochloridetablet1.5 mg/1oralScie Gen Pharmaceuticals Inc2014-10-29Not applicableUs
Pramipexole Dihydrochloridetablet.25 mg/1oralCardinal Health2011-05-01Not applicableUs
Pramipexole Dihydrochloridetablet.5 mg/1oralEndo Pharmaceuticals Inc. DBA Endo Generic Products2010-10-09Not applicableUs
Pramipexole Dihydrochloridetablet1 mg/1oralCadila Healthcare Limited2010-07-10Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-07-10Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralCitron Pharma LLC2012-10-26Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralTorrent Pharmaceuticals Limited2010-10-08Not applicableUs
Pramipexole Dihydrochloridetablet.25 mg/1oralMylan Pharmaceuticals Inc.2010-11-04Not applicableUs
Pramipexole Dihydrochloridetablet.25 mg/1oralMacleods Pharmaceuticals Limited2012-09-21Not applicableUs
Pramipexole Dihydrochloridetablet1 mg/1oralVensun Pharmaceuticals, Inc.2014-10-29Not applicableUs
Pramipexole Dihydrochloridetablet.25 mg/1oralPhysicians Total Care, Inc.2010-08-23Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralGolden State Medical Supply, Inc2014-10-29Not applicableUs
Pramipexole Dihydrochloridetablet.5 mg/1oralStrides Arcolab Limited2014-06-17Not applicableUs
Pramipexole Dihydrochloridetablet.25 mg/1oralAmerican Health Packaging2011-05-01Not applicableUs
Pramipexole Dihydrochloridetablet1 mg/1oralGlenmark Pharmaceuticals Inc., Usa2010-10-08Not applicableUs
Pramipexole Dihydrochloridetablet1.5 mg/1oralSandoz Inc2010-07-06Not applicableUs
Pramipexole Dihydrochloridetablet.25 mg/1oralWatson Pharma, Inc.2010-10-08Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralAv Kare, Inc.2013-09-05Not applicableUs
Pramipexole Dihydrochloridetablet1 mg/1oralScie Gen Pharmaceuticals Inc2014-10-29Not applicableUs
Pramipexole Dihydrochloridetablet, extended release4.5 mg/1oralDr. Reddy's Laboratories Limited2015-08-14Not applicableUs
Pramipexole Dihydrochloridetablet.25 mg/1oralEndo Pharmaceuticals Inc. DBA Endo Generic Products2010-10-09Not applicableUs
Pramipexole Dihydrochloridetablet.5 mg/1oralCadila Healthcare Limited2010-07-10Not applicableUs
Pramipexole Dihydrochloridetablet1.5 mg/1oralCarilion Materials Management2010-10-08Not applicableUs
Pramipexole Dihydrochloridetablet1.5 mg/1oralQualitest Pharmaceuticals2013-07-152016-01-20Us
Pramipexole Dihydrochloridetablet.25 mg/1oralSandoz Inc2010-07-06Not applicableUs
Pramipexole Dihydrochloridetablet.25 mg/1oralVensun Pharmaceuticals, Inc.2014-10-29Not applicableUs
Pramipexole Dihydrochloridetablet1.5 mg/1oralBreckenridge Pharmaceutical, Inc.2010-10-09Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralbryant ranch prepack2010-10-08Not applicableUs
Pramipexole Dihydrochloridetablet.75 mg/1oralAurobindo Pharma Limited2012-10-26Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralGlenmark Pharmaceuticals Inc., Usa2010-10-08Not applicableUs
Pramipexole Dihydrochloridetablet1.5 mg/1oralCitron Pharma LLC2012-10-26Not applicableUs
Pramipexole Dihydrochloridetablet.75 mg/1oralTorrent Pharmaceuticals Limited2010-10-08Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralMylan Pharmaceuticals Inc.2010-11-04Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralMacleods Pharmaceuticals Limited2012-09-21Not applicableUs
Pramipexole Dihydrochloridetablet.75 mg/1oralVensun Pharmaceuticals, Inc.2014-10-29Not applicableUs
Pramipexole Dihydrochloridetablet.5 mg/1oralPhysicians Total Care, Inc.2010-05-03Not applicableUs
Pramipexole Dihydrochloridetablet.25 mg/1oralStrides Arcolab Limited2014-06-17Not applicableUs
Pramipexole Dihydrochloridetablet1.5 mg/1oralAurobindo Pharma Limited2012-10-26Not applicableUs
Pramipexole Dihydrochloridetablet.5 mg/1oralGlenmark Pharmaceuticals Inc., Usa2010-10-08Not applicableUs
Pramipexole Dihydrochloridetablet1 mg/1oralSandoz Inc2010-07-06Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralWatson Pharma, Inc.2010-10-08Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-07-06Not applicableUs
Pramipexole Dihydrochloridetablet.75 mg/1oralScie Gen Pharmaceuticals Inc2014-10-29Not applicableUs
Pramipexole Dihydrochloridetablet, extended release3 mg/1oralDr. Reddy's Laboratories Limited2015-08-14Not applicableUs
Pramipexole Dihydrochloridetablet.125 mg/1oralEndo Pharmaceuticals Inc. DBA Endo Generic Products2010-10-09Not applicableUs
Pramipexole Dihydrochloridetablet.25 mg/1oralCadila Healthcare Limited2010-07-10Not applicableUs
Pramipexole Dihydrochloridetablet1 mg/1oralCarilion Materials Management2010-10-08Not applicableUs
Pramipexole Dihydrochloridetablet1 mg/1oralQualitest Pharmaceuticals2013-07-152016-01-20Us
Pramipexole Dihydrochloride Extended-releasetablet, extended release1.5 mg/1oralPar Pharmaceutical, Inc.2015-02-09Not applicableUs
Pramipexole Dihydrochloride Extended-releasetablet, extended release.75 mg/1oralPar Pharmaceutical, Inc.2015-02-09Not applicableUs
Pramipexole Dihydrochloride Extended-releasetablet, extended release.375 mg/1oralPar Pharmaceutical, Inc.2015-04-22Not applicableUs
Pramipexole Dihydrochloride Extended-releasetablet, extended release2.25 mg/1oralPar Pharmaceutical, Inc.2015-11-20Not applicableUs
Pramipexole Dihydrochloride Extended-releasetablet, extended release3 mg/1oralPar Pharmaceutical, Inc.2015-07-20Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
GleparkGlenmark
MedopexolMedochemie
MiramelClonmel
MiraperSpecifar
MirapexinBoehringer Ingelheim
PexolaBoehringer Ingelheim
SifrolBoehringer Ingelheim
Sifrol ERBoehringer Ingelheim
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Pramipexole dihydrochloride monohydrate
ThumbNot applicableDBSALT001198
Pramipexole hydrochloride
104632-25-9
Thumb
  • InChI Key: QMNWXHSYPXQFSK-KLXURFKVSA-N
  • Monoisotopic Mass: 283.067673727
  • Average Mass: 284.249
DBSALT000143
Categories
UNII83619PEU5T
CAS number104632-26-0
WeightAverage: 211.327
Monoisotopic: 211.114318249
Chemical FormulaC10H17N3S
InChI KeyInChIKey=FASDKYOPVNHBLU-ZETCQYMHSA-N
InChI
InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1
IUPAC Name
(6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
SMILES
CCCN[[email protected]]1CCC2=C(C1)SC(N)=N2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassAmines
Sub ClassAralkylamines
Direct ParentAralkylamines
Alternative Parents
Substituents
  • Aralkylamine
  • Primary aromatic amine
  • Heteroaromatic compound
  • Thiazole
  • Azole
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Primary amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of signs and symptoms of idiopathic Parkinson's disease
PharmacodynamicsPramipexole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is unknown. The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that Pramipexole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum.
Mechanism of actionThe precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum.
Related Articles
AbsorptionRapid. Absolute bioavailability is greater than 90%, indicating that pramipexole is well absorbed and undergoes little presystemic metabolism. Food does not affect the extent of absorption.
Volume of distribution
  • 500 L
Protein bindingAbout 15% bound to plasma proteins.
Metabolism

No metabolites have been identified in plasma or urine.

Route of eliminationUrinary excretion is the major route of pramipexole elimination, with 90% of a pramipexole dose recovered in urine, almost all as unchanged drug. Nonrenal routes may contribute to a small extent to pramipexole elimination, although no metabolites have been identified in plasma or urine.
Half life8 hours
Clearance
  • renal cl=400 mL/min
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9967
Blood Brain Barrier+0.9631
Caco-2 permeable-0.6419
P-glycoprotein substrateSubstrate0.6384
P-glycoprotein inhibitor INon-inhibitor0.842
P-glycoprotein inhibitor IINon-inhibitor0.7464
Renal organic cation transporterNon-inhibitor0.6788
CYP450 2C9 substrateNon-substrate0.8524
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7558
CYP450 1A2 substrateInhibitor0.9179
CYP450 2C9 inhibitorNon-inhibitor0.7353
CYP450 2D6 inhibitorInhibitor0.5364
CYP450 2C19 inhibitorInhibitor0.586
CYP450 3A4 inhibitorNon-inhibitor0.6708
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7797
Ames testNon AMES toxic0.8133
CarcinogenicityNon-carcinogens0.915
BiodegradationNot ready biodegradable0.9255
Rat acute toxicity2.8676 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8732
hERG inhibition (predictor II)Non-inhibitor0.8397
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Boehringer ingelheim
Packagers
Dosage forms
FormRouteStrength
Tabletoral0.75 mg
Tabletoral0.125 mg
Tabletoral0.25 mg
Tabletoral0.5 mg
Tabletoral1.0 mg
Tabletoral1.5 mg
Tablet, extended releaseoral.375 mg/1
Tablet, extended releaseoral.75 mg/1
Tablet, extended releaseoral1.5 mg/1
Tablet, extended releaseoral2.25 mg/1
Tablet, extended releaseoral3 mg/1
Tablet, extended releaseoral3.75 mg/1
Tablet, extended releaseoral4.5 mg/1
Tabletoral0.50 mg
Tabletoral1 mg
Tabletoral.125 mg/1
Tabletoral.25 mg/1
Tabletoral.5 mg/1
Tabletoral.75 mg/1
Tabletoral1 mg/1
Tabletoral1.5 mg/1
Prices
Unit descriptionCostUnit
Mirapex er 0.375 mg tablet9.83USD tablet
Mirapex er 0.75 mg tablet9.83USD tablet
Mirapex er 1.5 mg tablet9.83USD tablet
Mirapex er 3 mg tablet9.83USD tablet
Mirapex er 4.5 mg tablet9.83USD tablet
Mirapex 0.125 mg tablet3.48USD tablet
Mirapex 0.25 mg tablet3.42USD tablet
Mirapex 0.5 mg tablet3.42USD tablet
Mirapex 1 mg tablet3.42USD tablet
Mirapex 1.5 mg tablet3.42USD tablet
Mirapex 0.75 mg tablet3.28USD tablet
Pramipexole Dihydrochloride 0.125 mg tablet3.07USD tablet
Pramipexole Dihydrochloride 0.25 mg tablet3.07USD tablet
Pramipexole Dihydrochloride 0.5 mg tablet3.07USD tablet
Pramipexole Dihydrochloride 1 mg tablet3.07USD tablet
Pramipexole Dihydrochloride 1.5 mg tablet3.07USD tablet
Pramipexole di-hcl 0.125 mg tablet2.95USD tablet
Pramipexole di-hcl 0.25 mg tablet2.95USD tablet
Pramipexole di-hcl 0.5 mg tablet2.95USD tablet
Pramipexole di-hcl 1 mg tablet2.95USD tablet
Pramipexole di-hcl 1.5 mg tablet2.95USD tablet
Mirapex 1 mg Tablet2.2USD tablet
Mirapex 1.5 mg Tablet2.2USD tablet
Apo-Pramipexole 1 mg Tablet1.23USD tablet
Apo-Pramipexole 1.5 mg Tablet1.23USD tablet
Co Pramipexole 1 mg Tablet1.23USD tablet
Co Pramipexole 1.5 mg Tablet1.23USD tablet
Novo-Pramipexole 1 mg Tablet1.23USD tablet
Novo-Pramipexole 1.5 mg Tablet1.23USD tablet
Pms-Pramipexole 1 mg Tablet1.23USD tablet
Pms-Pramipexole 1.5 mg Tablet1.23USD tablet
Sandoz Pramipexole 1 mg Tablet1.23USD tablet
Sandoz Pramipexole 1.5 mg Tablet1.23USD tablet
Mirapex 0.25 mg Tablet1.1USD tablet
Apo-Pramipexole 0.25 mg Tablet0.62USD tablet
Co Pramipexole 0.25 mg Tablet0.62USD tablet
Novo-Pramipexole 0.25 mg Tablet0.62USD tablet
Pms-Pramipexole 0.25 mg Tablet0.62USD tablet
Sandoz Pramipexole 0.25 mg Tablet0.62USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2275379 No2006-11-282018-01-16Canada
US4886812 No1993-10-082010-10-08Us
US6001861 No1998-01-162018-01-16Us
US6194445 No1998-01-162018-01-16Us
US7695734 No2008-04-262028-04-26Us
US8679533 No2009-09-082029-09-08Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP0.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.14 mg/mLALOGPS
logP2.18ALOGPS
logP1.76ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)17.66ChemAxon
pKa (Strongest Basic)10.31ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area50.94 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity59.77 m3·mol-1ChemAxon
Polarizability24.47 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

DrugSyn.org

US4886812
General References
  1. Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM: Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol. 1995 Jun 23;290(1):29-36. [PubMed:7664822 ]
External Links
ATC CodesN04BC05
AHFS Codes
  • 28:36.20.08
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AlfentanilAlfentanil may increase the sedative activities of Pramipexole.
AlprazolamAlprazolam may increase the sedative activities of Pramipexole.
AmisulprideThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Pramipexole.
AmitriptylineAmitriptyline may increase the sedative activities of Pramipexole.
AmobarbitalAmobarbital may increase the sedative activities of Pramipexole.
AmoxapineAmoxapine may increase the sedative activities of Pramipexole.
AzelastineAzelastine may increase the sedative activities of Pramipexole.
BaclofenBaclofen may increase the sedative activities of Pramipexole.
BrimonidineBrimonidine may increase the sedative activities of Pramipexole.
BromazepamBromazepam may increase the sedative activities of Pramipexole.
BrompheniramineBrompheniramine may increase the sedative activities of Pramipexole.
BuprenorphineBuprenorphine may increase the sedative activities of Pramipexole.
BupropionThe risk or severity of adverse effects can be increased when Pramipexole is combined with Bupropion.
BuspironeBuspirone may increase the sedative activities of Pramipexole.
ButabarbitalButabarbital may increase the sedative activities of Pramipexole.
ButorphanolButorphanol may increase the sedative activities of Pramipexole.
CarbamazepineCarbamazepine may increase the sedative activities of Pramipexole.
CarbinoxamineCarbinoxamine may increase the sedative activities of Pramipexole.
CarisoprodolCarisoprodol may increase the sedative activities of Pramipexole.
CetirizineCetirizine may increase the sedative activities of Pramipexole.
ChlordiazepoxideChlordiazepoxide may increase the sedative activities of Pramipexole.
ChlorphenamineChlorphenamine may increase the sedative activities of Pramipexole.
ChlorzoxazoneChlorzoxazone may increase the sedative activities of Pramipexole.
CimetidineThe serum concentration of Pramipexole can be increased when it is combined with Cimetidine.
ClemastineClemastine may increase the sedative activities of Pramipexole.
ClobazamClobazam may increase the sedative activities of Pramipexole.
ClomipramineClomipramine may increase the sedative activities of Pramipexole.
ClonazepamClonazepam may increase the sedative activities of Pramipexole.
ClonidineClonidine may increase the sedative activities of Pramipexole.
ClorazepateClorazepate may increase the sedative activities of Pramipexole.
CyclizineCyclizine may increase the sedative activities of Pramipexole.
CyclobenzaprineCyclobenzaprine may increase the sedative activities of Pramipexole.
CyproheptadineCyproheptadine may increase the sedative activities of Pramipexole.
DantroleneDantrolene may increase the sedative activities of Pramipexole.
DesfluraneDesflurane may increase the sedative activities of Pramipexole.
DesipramineDesipramine may increase the sedative activities of Pramipexole.
DesloratadineDesloratadine may increase the sedative activities of Pramipexole.
Dexchlorpheniramine maleateDexchlorpheniramine maleate may increase the sedative activities of Pramipexole.
DiazepamDiazepam may increase the sedative activities of Pramipexole.
DimenhydrinateDimenhydrinate may increase the sedative activities of Pramipexole.
DiphenhydramineDiphenhydramine may increase the sedative activities of Pramipexole.
DoxepinDoxepin may increase the sedative activities of Pramipexole.
DoxylamineDoxylamine may increase the sedative activities of Pramipexole.
EfavirenzEfavirenz may increase the sedative activities of Pramipexole.
EntacaponeEntacapone may increase the sedative activities of Pramipexole.
EstazolamEstazolam may increase the sedative activities of Pramipexole.
EszopicloneEszopiclone may increase the sedative activities of Pramipexole.
EthanolEthanol may increase the sedative activities of Pramipexole.
EthosuximideEthosuximide may increase the sedative activities of Pramipexole.
EthotoinEthotoin may increase the sedative activities of Pramipexole.
EzogabineEzogabine may increase the sedative activities of Pramipexole.
FelbamateFelbamate may increase the sedative activities of Pramipexole.
FentanylFentanyl may increase the sedative activities of Pramipexole.
FexofenadineFexofenadine may increase the sedative activities of Pramipexole.
FlibanserinFlibanserin may increase the sedative activities of Pramipexole.
FlunarizineFlunarizine may increase the sedative activities of Pramipexole.
FlurazepamFlurazepam may increase the sedative activities of Pramipexole.
FosphenytoinFosphenytoin may increase the sedative activities of Pramipexole.
GabapentinGabapentin may increase the sedative activities of Pramipexole.
gabapentin enacarbilgabapentin enacarbil may increase the sedative activities of Pramipexole.
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the sedative activities of Pramipexole.
GuanfacineGuanfacine may increase the sedative activities of Pramipexole.
HydrocodoneHydrocodone may increase the sedative activities of Pramipexole.
HydromorphoneHydromorphone may increase the sedative activities of Pramipexole.
HydroxyzineHydroxyzine may increase the sedative activities of Pramipexole.
ImipramineImipramine may increase the sedative activities of Pramipexole.
IsofluraneIsoflurane may increase the sedative activities of Pramipexole.
KetamineKetamine may increase the sedative activities of Pramipexole.
LamotrigineLamotrigine may increase the sedative activities of Pramipexole.
LevetiracetamLevetiracetam may increase the sedative activities of Pramipexole.
LevocabastineLevocabastine may increase the sedative activities of Pramipexole.
LevocetirizineLevocetirizine may increase the sedative activities of Pramipexole.
LevorphanolLevorphanol may increase the sedative activities of Pramipexole.
LoratadineLoratadine may increase the sedative activities of Pramipexole.
LorazepamLorazepam may increase the sedative activities of Pramipexole.
LoxapineThe therapeutic efficacy of Loxapine can be decreased when used in combination with Pramipexole.
MaprotilineMaprotiline may increase the sedative activities of Pramipexole.
MeclizineMeclizine may increase the sedative activities of Pramipexole.
MeprobamateMeprobamate may increase the sedative activities of Pramipexole.
MetaxaloneMetaxalone may increase the sedative activities of Pramipexole.
MethadoneMethadone may increase the sedative activities of Pramipexole.
MethocarbamolMethocarbamol may increase the sedative activities of Pramipexole.
MethohexitalMethohexital may increase the sedative activities of Pramipexole.
MethsuximideMethsuximide may increase the sedative activities of Pramipexole.
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Pramipexole.
MetoclopramideThe therapeutic efficacy of Pramipexole can be decreased when used in combination with Metoclopramide.
MidazolamMidazolam may increase the sedative activities of Pramipexole.
MirtazapineMirtazapine may increase the sedative activities of Pramipexole.
MorphineMorphine may increase the sedative activities of Pramipexole.
NalbuphineNalbuphine may increase the sedative activities of Pramipexole.
NitrazepamNitrazepam may increase the sedative activities of Pramipexole.
Nitrous oxideNitrous oxide may increase the sedative activities of Pramipexole.
NortriptylineNortriptyline may increase the sedative activities of Pramipexole.
OlopatadineOlopatadine may increase the sedative activities of Pramipexole.
OrphenadrineOrphenadrine may increase the sedative activities of Pramipexole.
OxazepamOxazepam may increase the sedative activities of Pramipexole.
OxycodoneOxycodone may increase the sedative activities of Pramipexole.
OxymorphoneOxymorphone may increase the sedative activities of Pramipexole.
ParaldehydeParaldehyde may increase the sedative activities of Pramipexole.
PentazocinePentazocine may increase the sedative activities of Pramipexole.
PentobarbitalPentobarbital may increase the sedative activities of Pramipexole.
PerampanelPerampanel may increase the sedative activities of Pramipexole.
PethidinePethidine may increase the sedative activities of Pramipexole.
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Pramipexole.
PhenobarbitalPhenobarbital may increase the sedative activities of Pramipexole.
PhenytoinPhenytoin may increase the sedative activities of Pramipexole.
PipotiazinePipotiazine may increase the sedative activities of Pramipexole.
PizotifenPizotifen may increase the sedative activities of Pramipexole.
PomalidomidePomalidomide may increase the sedative activities of Pramipexole.
PregabalinPregabalin may increase the sedative activities of Pramipexole.
PrimidonePrimidone may increase the sedative activities of Pramipexole.
PromethazinePromethazine may increase the sedative activities of Pramipexole.
PropofolPropofol may increase the sedative activities of Pramipexole.
ProtriptylineProtriptyline may increase the sedative activities of Pramipexole.
QuazepamQuazepam may increase the sedative activities of Pramipexole.
RamelteonRamelteon may increase the sedative activities of Pramipexole.
RemifentanilRemifentanil may increase the sedative activities of Pramipexole.
ReserpineReserpine may increase the sedative activities of Pramipexole.
ScopolamineScopolamine may increase the sedative activities of Pramipexole.
Scopolamine butylbromideScopolamine butylbromide may increase the sedative activities of Pramipexole.
SecobarbitalSecobarbital may increase the sedative activities of Pramipexole.
SevofluraneSevoflurane may increase the sedative activities of Pramipexole.
Sodium oxybateSodium oxybate may increase the sedative activities of Pramipexole.
StiripentolStiripentol may increase the sedative activities of Pramipexole.
SufentanilSufentanil may increase the sedative activities of Pramipexole.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pramipexole.
SuvorexantSuvorexant may increase the sedative activities of Pramipexole.
TapentadolTapentadol may increase the sedative activities of Pramipexole.
TasimelteonTasimelteon may increase the sedative activities of Pramipexole.
TemazepamTemazepam may increase the sedative activities of Pramipexole.
TetrabenazineTetrabenazine may increase the sedative activities of Pramipexole.
ThalidomideThalidomide may increase the sedative activities of Pramipexole.
TiagabineTiagabine may increase the sedative activities of Pramipexole.
TizanidineTizanidine may increase the sedative activities of Pramipexole.
TolcaponeTolcapone may increase the sedative activities of Pramipexole.
TopiramateTopiramate may increase the sedative activities of Pramipexole.
TramadolTramadol may increase the sedative activities of Pramipexole.
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Pramipexole.
TriazolamTriazolam may increase the sedative activities of Pramipexole.
TrimipramineTrimipramine may increase the sedative activities of Pramipexole.
TriprolidineTriprolidine may increase the sedative activities of Pramipexole.
VigabatrinVigabatrin may increase the sedative activities of Pramipexole.
ZaleplonZaleplon may increase the sedative activities of Pramipexole.
ZiconotideZiconotide may increase the sedative activities of Pramipexole.
ZiprasidoneThe therapeutic efficacy of Pramipexole can be decreased when used in combination with Ziprasidone.
ZolpidemZolpidem may increase the sedative activities of Pramipexole.
ZonisamideZonisamide may increase the sedative activities of Pramipexole.
ZopicloneZopiclone may increase the sedative activities of Pramipexole.
Food Interactions
  • Take without regard to meals, however if nausea is a problem, taking the product with food may reduce its incidence.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
partial agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Ishiguro N, Saito A, Yokoyama K, Morikawa M, Igarashi T, Tamai I: Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. Drug Metab Dispos. 2005 Apr;33(4):495-9. Epub 2005 Jan 7. [PubMed:15640376 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Ishiguro N, Saito A, Yokoyama K, Morikawa M, Igarashi T, Tamai I: Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. Drug Metab Dispos. 2005 Apr;33(4):495-9. Epub 2005 Jan 7. [PubMed:15640376 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on July 26, 2016 01:53